BiotechTube

Pembrolizumab Injection

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors

Trial Timeline

Dec 4, 2017 → Mar 11, 2019

NCT ID
NCT03190213

About Pembrolizumab Injection

Pembrolizumab Injection is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT03190213. Target conditions include Neuroendocrine Tumors.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04808999Phase 2Active
NCT03190213Phase 2Terminated

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
25
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
25
LenvatinibEisaiPhase 2
52
AbemaciclibEli LillyPhase 2
52
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
77
OlaparibAstraZenecaPhase 2
52
AvelumabMerckPhase 1/2
41
PembrolizumabMerckPhase 2
52
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
52
Pembrolizumab + LenvatinibMerckPhase 2
52
AvelumabMerckPhase 2
52
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
52
MK-0646MerckPhase 2
52
Lanreotide + PembrolizumabMerckPhase 1/2
41

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85